DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Summary

This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. This study will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and assess its anti-cancer activity as monotherapy.

Timeline

Start

2023-05-15

Primary completion

2025-06-30

Completion

2025-06-30

Drugs

Indications